245 related articles for article (PubMed ID: 14738561)
1. Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy.
Werle B; Cinquin K; Marcellin P; Pol S; Maynard M; Trépo C; Zoulim F
J Viral Hepat; 2004 Jan; 11(1):74-83. PubMed ID: 14738561
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
3. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
[TBL] [Abstract][Full Text] [Related]
4. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
Suzuki F; Kumada H; Nakamura H
J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
[TBL] [Abstract][Full Text] [Related]
5. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
[TBL] [Abstract][Full Text] [Related]
6. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.
Lutgehetmann M; Volzt T; Quaas A; Zankel M; Fischer C; Dandri M; Petersen J
Antivir Ther; 2008; 13(1):57-66. PubMed ID: 18389899
[TBL] [Abstract][Full Text] [Related]
7. Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.
Liu Y; Liu W; Li X; Xu Z; Wang X; Li C; Chen L; Xin S; Xu D
Antivir Ther; 2014; 19(6):551-8. PubMed ID: 24710668
[TBL] [Abstract][Full Text] [Related]
8. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
Ling N; Zhou Z; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
10. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.
Angus P; Vaughan R; Xiong S; Yang H; Delaney W; Gibbs C; Brosgart C; Colledge D; Edwards R; Ayres A; Bartholomeusz A; Locarnini S
Gastroenterology; 2003 Aug; 125(2):292-7. PubMed ID: 12891527
[TBL] [Abstract][Full Text] [Related]
11. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
Idilman R; Kaymakoglu S; Oguz Onder F; Ahishali E; Bektas M; Cinar K; Pinarbasi B; Karayalcin S; Badur S; Cakaloglu Y; Mithat Bozdayi A; Bozkaya H; Okten A; Yurdaydin C
J Viral Hepat; 2009 Apr; 16(4):279-85. PubMed ID: 19222742
[TBL] [Abstract][Full Text] [Related]
12. A novel baseline hepatitis B virus sequencing-based strategy for predicting adefovir antiviral response.
Wang YW; Shan X; Huang Y; Deng H; Huang WX; Zhang DZ; Chen J; Tang N; Shan YL; Guo JJ; Huang A
Infect Genet Evol; 2015 Jul; 33():269-76. PubMed ID: 25983054
[TBL] [Abstract][Full Text] [Related]
13. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
Chang UI; Lee YC; Wie SH; Jang JW; Bae SH; Choi JY; Yang JM; Yoon SK; Sun HS
J Med Virol; 2007 Jul; 79(7):902-10. PubMed ID: 17516533
[TBL] [Abstract][Full Text] [Related]
14. [Dissection of mechanism for the adefovir dipivoxil resistance in chronic hepatitis B patients].
Zeng AZ; Lu P; Deng H; Cai SF; Yang C; Xin XJ; Guo JJ; Li QL; Deng XH; Huang AL
Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):730-4. PubMed ID: 19874686
[TBL] [Abstract][Full Text] [Related]
15. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
16. Increased occurrence of mutant rtI233V of HBV in patients receiving adefovir therapy.
Liu Y; Xin S; Ye X; Chen R; Xu Z; Li X; Ye H; Cheng S; Xu D
Antivir Ther; 2016; 21(1):9-16. PubMed ID: 26079809
[TBL] [Abstract][Full Text] [Related]
17. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
[TBL] [Abstract][Full Text] [Related]
18. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).
Osiowy C; Villeneuve JP; Heathcote EJ; Giles E; Borlang J
J Clin Microbiol; 2006 Jun; 44(6):1994-7. PubMed ID: 16757589
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
[TBL] [Abstract][Full Text] [Related]
20. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
Lau GK; Cooksley H; Ribeiro RM; Powers KA; Shudo E; Bowden S; Hui CK; Anderson J; Sorbel J; Mondou E; Rousseau F; Lewin S; Perelson AS; Locornini S; Naoumov NV
Antivir Ther; 2007; 12(5):705-18. PubMed ID: 17713154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
